Changeflow GovPing Pharma & Drug Safety SK Biopharmaceuticals Oxadiazole Epilepsy Treat...
Routine Rule Added Final

SK Biopharmaceuticals Oxadiazole Epilepsy Treatment Patent EP3854788A1

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3854788A1 for SK Biopharmaceuticals' oxadiazole derivatives used in the treatment of epilepsy. The patent covers heterocyclic compounds classified under C07D271/10 with pharmaceutical applications (A61P25/08, A61K31/4245). The patent lists 16 inventors and designates 32 European states including all major EU markets.

What changed

The EPO published patent EP3854788A1 granting SK Biopharmaceuticals exclusive rights to oxadiazole derivatives for epilepsy treatment. The patent covers compounds under IPC classification C07D271/10 and pharmaceutical composition claims (A61K31/4245) for treating epilepsy (A61P25/08).

Pharmaceutical companies developing competing epilepsy treatments in Europe should assess freedom-to-operate implications. Generic manufacturers and biosimilar developers may need to design around this patent or seek licensing arrangements for any overlapping compound claims.

What to do next

  1. Monitor patent landscape for epilepsy treatment developments
  2. Review freedom-to-operate for any competing oxadiazole-based therapies in Europe

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF EPILEPSY

Publication EP3854788A1 Kind: A1 Apr 01, 2026

Applicants

SK Biopharmaceuticals Co., Ltd.

Inventors

RYU, Choon Ho, HAN, Min Soo, YOON, Yeo Jin, KIM, Yu Jin, LEE, Ka Eun, LEE, Ju Young, JUNG, Myung Jin, BAEK, Eun Hee, SHIN, Yu Jin, CHOI, Eun Ju, KANG, Young Soon, KIM, Yong Soo, SONG, Yea Mi, KIM, Jin Sung, LIM, Hee Jeong

IPC Classifications

C07D 271/10 20060101AFI20220512BHEP C07D 271/06 20060101ALI20220512BHEP A61P 25/08 20060101ALI20220512BHEP A61K 31/4245 20060101ALI20220512BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3854788A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent prosecution Drug development Epilepsy treatment research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.